NOV Inc. Common Stock vs Novartis AG — how do they compare? NOV Inc. Common Stock trades at $19.15 (market cap $6.77B), while Novartis AG trades at $143.11 (market cap $268.57B). The key difference: Novartis AG is far larger — about 39.7× NOV Inc. Common Stock's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold NOV Inc. Common Stock for 0 Days and Novartis AG for 82 Days on average.
| NOV | NVS | |
|---|---|---|
Market Cap | $6.77B | $268.57B |
Volume | 3,592,724 | 1,532,573 |
Sector | Energy | Health |
52-Week High | $21.71 | $168.62 |
52-Week Low | $12.31 | $121.80 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $7.93B | $309.89B |
Dividend Yield | 1.9% | 3.31% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
NOV provides technology, equipment, and services for energy production. Its offerings support drilling, well construction, and production across oil, gas, renewables, and emerging energy markets.
Read more on NOV →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →